KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Staar Surgical (STAA) EBITDA (2016 - 2026)

Staar Surgical (STAA) has disclosed EBITDA for 17 consecutive years, with -$22.8 million as the latest value for Q1 2026.

  • For the quarter ending Q1 2026, EBITDA rose 18.17% year-over-year to -$22.8 million, compared with a TTM value of -$91.7 million through Jan 2026, down 627.25%, and an annual FY2026 reading of -$91.7 million, down 627.25% over the prior year.
  • EBITDA was -$22.8 million for Q1 2026 at Staar Surgical, down from $18.5 million in the prior quarter.
  • Across five years, EBITDA topped out at $18.5 million in Q3 2025 and bottomed at -$57.4 million in Q1 2025.
  • Average EBITDA over 5 years is -$3.3 million, with a median of $4.2 million recorded in 2023.
  • Peak annual rise in EBITDA hit 225.41% in 2025, while the deepest fall reached 2416.48% in 2025.
  • Year by year, EBITDA stood at $964000.0 in 2022, then plummeted by 1201.24% to -$10.6 million in 2023, then plummeted by 162.91% to -$27.9 million in 2024, then skyrocketed by 166.25% to $18.5 million in 2025, then plummeted by 223.52% to -$22.8 million in 2026.
  • Business Quant data shows EBITDA for STAA at -$22.8 million in Q1 2026, $18.5 million in Q3 2025, and -$30.0 million in Q2 2025.